Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:51:15 EDT Tue 20 May 2025
Enter Symbol
or Name
USA
CA



Q:BCLI - BRAINSTROM CELL THERAPEUTICS - https://www.brainstorm-cell.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCLI - Q0.11.23·1.250.11.36307.5272356    10.0485  0.723308:32:39May 1915 min RT 2¢

Recent Trades - Last 10 of 356
Time ETExPriceChangeVolume
08:32:39Q1.2495-0.1105100
08:31:59Q1.2491-0.1109254
08:31:48Q1.23-0.1356
08:30:54Q1.2492-0.1108100
08:30:43Q1.23-0.131,300
08:30:37Q1.24-0.1299
08:29:22Q1.2498-0.11021
08:28:49Q1.23-0.13124
08:28:39Q1.2306-0.12941,000
08:27:09Q1.26-0.1025

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-19 07:00U:BCLINews ReleaseBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(TM) for ALS
2025-05-15 16:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-15 07:30U:BCLINews ReleaseBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
2025-05-07 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
2025-05-06 07:00U:BCLINews ReleaseBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
2025-04-29 06:30U:BCLINews ReleaseBrainStorm's NurOwn(TM) Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
2025-04-10 07:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(TM) in ALS
2025-03-31 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-26 08:15U:BCLINews ReleaseBrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
2025-03-24 07:00U:BCLINews ReleaseBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
2024-12-30 08:00U:BCLINews ReleaseBrainStorm Issues 2024 Letter to Shareholders
2024-12-09 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
2024-12-03 07:00U:BCLINews ReleaseBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
2024-12-02 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
2024-11-14 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-11 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn(TM) Phase 3b Trial Manufacturing
2024-10-30 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-10-28 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn(TM) Expanded Access Program at 2024 Annual NEALS Meeting
2024-10-07 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn(TM) Trial at the 2024 Maxim Healthcare Virtual Summit
2024-09-24 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Presentations on NurOwn(TM) at 2024 Annual NEALS Meeting